Abstract
We conducted a case-control study to assess testosterone use as a primary risk factor for polycythemia in 21 HIV-infected men. Any testosterone use within 2 months of first elevated hemoglobin was associated with polycythemia (matched odds ratio 6.55; 95% confidence interval 1.83-23.4; P = 0.004) and intramuscular administration demonstrated a stronger association than topical use. No adverse cardiovascular or thrombotic events were observed. HIV-infected patients taking testosterone should undergo routine hematologic monitoring with adjustment of therapy when appropriate.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Administration, Cutaneous
-
Androgens / administration & dosage
-
Androgens / adverse effects*
-
Androgens / blood
-
Case-Control Studies
-
HIV Seropositivity / blood*
-
HIV Seropositivity / complications
-
Hemoglobins / metabolism
-
Hormone Replacement Therapy / adverse effects*
-
Humans
-
Hypogonadism / drug therapy
-
Injections, Intramuscular
-
Male
-
Middle Aged
-
Odds Ratio
-
Polycythemia / blood*
-
Polycythemia / chemically induced*
-
Polycythemia / epidemiology
-
Retrospective Studies
-
Risk Assessment
-
Testosterone / administration & dosage
-
Testosterone / adverse effects*
-
Testosterone / blood
-
Time Factors
Substances
-
Androgens
-
Hemoglobins
-
Testosterone